Grifols, S.A. (GRFS) To Go Ex-Dividend on July 2nd

Grifols, S.A. (NASDAQ:GRFS) declared a special dividend on Monday, June 22nd. Shareholders of record on Thursday, July 2nd will be paid a dividend of 0.0945 per share by the biotechnology company on Thursday, July 9th. The ex-dividend date of this dividend is Thursday, July 2nd.

Grifols has a payout ratio of 12.7% indicating that its dividend is sufficiently covered by earnings. Equities research analysts expect Grifols to earn $1.34 per share next year, which means the company should continue to be able to cover its $0.14 annual dividend with an expected future payout ratio of 10.4%.

Grifols Stock Performance

Shares of Grifols stock opened at $7.18 on Wednesday. Grifols has a 12 month low of $7.16 and a 12 month high of $11.14. The firm has a market capitalization of $4.89 billion, a P/E ratio of 37.79, a P/E/G ratio of 0.28 and a beta of 0.65. The company has a current ratio of 2.47, a quick ratio of 0.85 and a debt-to-equity ratio of 1.16. The business has a fifty day simple moving average of $7.90 and a two-hundred day simple moving average of $8.50.

Grifols (NASDAQ:GRFS) last released its earnings results on Saturday, February 14th. The biotechnology company reported $0.38 earnings per share for the quarter. Grifols had a net margin of 5.54% and a return on equity of 6.21%. The firm had revenue of $2.32 billion for the quarter. On average, equities analysts forecast that Grifols will post 1.06 earnings per share for the current fiscal year.

Institutional Trading of Grifols

Several institutional investors have recently added to or reduced their stakes in GRFS. Mirae Asset Global Investments Co. Ltd. raised its stake in shares of Grifols by 25.7% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,928 shares of the biotechnology company’s stock worth $55,000 after purchasing an additional 1,212 shares during the last quarter. PNC Financial Services Group Inc. boosted its position in shares of Grifols by 50.3% during the first quarter. PNC Financial Services Group Inc. now owns 8,961 shares of the biotechnology company’s stock valued at $72,000 after buying an additional 2,998 shares during the last quarter. EverSource Wealth Advisors LLC increased its holdings in Grifols by 127.4% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 8,219 shares of the biotechnology company’s stock worth $74,000 after buying an additional 4,604 shares in the last quarter. Allworth Financial LP increased its holdings in Grifols by 15.7% in the 4th quarter. Allworth Financial LP now owns 8,073 shares of the biotechnology company’s stock worth $75,000 after buying an additional 1,096 shares in the last quarter. Finally, Ameriprise Financial Inc. purchased a new position in Grifols in the 2nd quarter worth about $95,000.

Grifols Company Profile

Grifols, Inc (NASDAQ: GRFS) is a global healthcare company specializing in the development, manufacture and marketing of plasma-derived medicines, diagnostic systems and hospital supplies. With a core focus on immunotherapy and transfusion medicine, the company harnesses human plasma proteins to create therapies that treat a wide range of bleeding disorders, immunodeficiencies and neurological conditions. Grifols also supplies reagents and diagnostic instruments for transfusion centers and clinical laboratories, alongside intravenous solutions and medical devices for hospital use.

The company operates three main business units.